# US 5,030,714 A · Variant of LAV viruses > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,030,714 A - Document ID: US5030714A - Status: Granted - Kind: A - Application number: 07/038,330 - Filed: 1987-04-13 - Granted: 1991-07-09 - Earliest claimed: 1986-06-23 - Assignees: Institut Pasteur - Inventors: Marc Alizon; Pierre Sonigo; Simon Wain-Hobson; Luc Montagnier - Web page: https://patentgrep.com/patent/US5030714A ## CPC - C12Q 1/702: {for retroviruses} - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - C12Q 1/703: {Viruses associated with AIDS} - G01N 33/56988: {HIV or HTLV} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C12N 2740/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2740/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2740/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2740/16051: Methods of production or purification of viral material - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A variant of the LAV virus, designated LAV.sub.MAL and capable of causing AIDS. The cDNA and antigens of the LAV.sub.MAL virus can be used for the diagnosis of AIDS and pre-AIDS. ## Claims ### Claim 1 An isolated or synthetic peptide comprising an amino acid sequence that is a fragment of the following amino acid sequence: ##STR1## wherein, in said amino acid sequence, A is alanine, C is cysteine, D is aspartic acid, E is glutamic acid, F is phenylalanine, G is glycine, H is histidine, I is isoleucine, K is lysine, L is leucine, M is methionine, N is asparagine, P is proline, Q is glutamine, R is arginine, S is serine, T is threonine, V is valine, W is tryptophan, and Y is tyrosine, and wherein said fragment comprises at least one amino acid sequence selected from the group consisting of amino-acyl residue 37-130, amino-acyl residues 211-289, amino-acyl residues 488-530, amino-acyl residues 490-620, amino-acyl residues 680-700, amino-acyl residues 1-530, amino-acyl residues 34-530, amino-acyl residues 531-877 of an envelope glycoprotein of LAV.sub.MAL virus. ### Claim 2 (depends on 1) An immunogenic composition comprising an isolated or synthetic peptide as claimed in claim 1 and a physiologically acceptable carrier, wherein said immunogenic composition is capable of eliciting an immune response to said peptide in a host. ### Claim 3 (depends on 2) An immunogenic composition as claimed in claim 2, wherein said peptide is coupled to a physiologically acceptable and non-toxic carrier molecule that is capable of enhancing the immunogenicity of the peptide. ### Claim 4 (depends on 3) An immunogenic composition as claimed in claim 3, wherein said carrier molecule is a natural protein or a synthetic macromolecular carrier. ### Claim 5 (depends on 4) An immunogenic composition as claimed in claim 4, wherein said natural protein is selected from the group consisting of tetanus toxoid, ovalbumin, serum albumin, and hemocyanin. ### Claim 6 (depends on 4) An immunogenic composition as claimed in claim 4, wherein said synthetic macromolecular carrier is polylysine or poly(D-L alanine)-poly(L-lysine). ### Claim 7 (depends on 1) The peptide of claim 1, wherein said peptide is a glycoprotein. ### Claim 8 (depends on 1) An isolated or synthetic peptide as claimed in claim 1, wherein said fragment comprises amino-acyl residues 37-130 of the envelope glycoprotein of LAV.sub.MAL virus. ### Claim 9 (depends on 1) An isolated or synthetic peptide as claimed in claim 1, wherein said fragment comprises amino-acyl residues 211-289 of the envelope glycoprotein of LAV.sub.MAL virus. ### Claim 10 (depends on 1) An isolated or synthetic peptide as claimed in claim 1, wherein said fragment comprises amino-acyl residues 488-530 of the envelope glycoprotein of LAV.sub.MAL virus. ### Claim 11 (depends on 1) An isolated or synthetic peptide as claimed in claim 1, wherein said fragment comprises amino-acyl residues 490-620 of the envelope glycoprotein of LAV.sub.MAL virus. ### Claim 12 (depends on 1) An isolated or synthetic peptide as claimed in claim 1, wherein said fragment comprises amino-acyl residues 680-700 of the envelope glycoprotein of LAV.sub.MAL virus. ### Claim 13 (depends on 1) An isolated or synthetic peptide as claimed in claim 1, wherein said fragment comprises amino-acyl residues 1-530 of the envelope glycoprotein of LAV.sub.MAL virus. ### Claim 14 (depends on 1) An isolated or synthetic peptide as claimed in claim 1, wherein said fragment comprises amino-acyl residues 34-530 of the envelope glycoprotein of LAV.sub.MAL virus. ### Claim 15 (depends on 1) An isolated or synthetic peptide as claimed in claim 1, wherein said fragment comprises amino-acyl residues 531-877 of the envelope glycoprotein of LAV.sub.MAL virus. ### Claim 16 An isolated or synthetic peptide comprising an amino acid sequence that is a fragment of the following amino acid sequence: ##STR2## wherein, in said amino acid sequence, A is alanine, C is cysteine, D is aspartic acid, E is glutamic acid, F is phenylalanine, G is glycine, H is histidine, I is isoleucine, K is lysine, L is leucine, M is methionine, N is asparagine, P is proline, Q is glutamine, R is arginine, S is serine, T is threonine, V is valine, W is tryptophan, and Y is tyrosine, and wherein said fragment comprises a p25 peptide comprising amino-acyl residues 138-385 of gag protein of LAV.sub.MAL virus. ### Claim 17 (depends on 16) An immunogenic composition comprising an isolated or synthetic peptide as claimed in claim 16 and a physiologically acceptable carrier, wherein immunogenic composition is capable of eliciting an immune response to said peptide in a host. ### Claim 18 An isolated or synthetic peptide comprising an amino acid sequence that is a fragment of the following amino acid sequence: ##STR3## wherein, in said amino acid sequence, A is alanine, C is cysteine, D is aspartic acid, E is glutamic acid, F is phenylalanine, G is glycine, H is histidine, I is isoleucine, K is lysine, L is leucine, M is methionine, N is asparagine, P is proline, Q is glutamine, R is arginine, S is serine, T is threonine, V is valine, W is tryptophan, and Y is tyrosine, and wherein said fragment comprises a p13 peptide comprising amino-acyl residues 385-519 of gag protein of LAV.sub.MAL virus. ### Claim 19 (depends on 18) An immunogenic composition comprising an isolated or synthetic peptide as claimed in claim 18 and a physiologically acceptable carrier, wherein immunogenic composition is capable of eliciting an immune response to said peptide in a host. ### Claim 20 An isolated or synthetic peptide comprising an amino acid sequence: ##STR4## wherein, in said amino acid sequence, A is alanine, C is cysteine, D is aspartic acid, E is glutamic acid, F is phenylalanine, G is glycine, H is histidine, I is isoleucine, K is lysine, L is leucine, M is methionine, N is asparagine, P is proline, Q is glutamine, R is arginine, S is serine, T is threonine, V is valine, W is tryptophan, and Y is tyrosine.